𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A multigene test for the risk of sporadic breast carcinoma

✍ Scribed by David E. Comings; Radhika Gade-Andavolu; Lawrence A. Cone; Donn Muhleman; James P. MacMurray


Book ID
102108206
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
125 KB
Volume
97
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

BACKGROUND

Although the identification of the BRCA1 and BRCA2 genes have been of great interest, these genes account for less than 5% of all breast carcinoma cases. The remaining cases are sporadic. Reanalysis of a large twin study suggested that genetic factors may play a significant role in sporadic breast and other carcinomas. Sporadic breast carcinoma is polygenically inherited. Multiple genes are likely to have an additive effect, each gene accounting for a fraction of the variance. One factor that may have an impact on the development of hormonally responsive breast tumors is the duration of exposure of the breast to estrogen. Therefore, one of the demographic risk factors for breast carcinoma is an early age of onset of menarche. The current study was based on the hypothesis that genes that play a role in demographic risk factors may be breast carcinoma risk genes in their own right. The authors hypothesized that six genes relevant to the timing of the onset of menarche and related risk factors might be candidate genes for breast carcinoma. These were the leptin gene (LEP), the leptin receptor gene (LEPR), the catechol‐0‐methyltransferase gene (COMT), the dopamine D~2~ receptor gene (DRD2), the estrogen 1 receptor gene (ESR1), and the androgen receptor gene (AR).

METHODS

The authors examined 67 women with postmenopausal sporadic breast carcinoma and 145 gender and race‐matched controls.

RESULTS

Five of these genes accounted for a significant percent of the variance (r^2^) of breast carcinoma. The following r^2^ and P values were calculated: LEP: 0.073, P ≀ 0.0001; LEPR: 0.064, P ≀ 0.0002; COMT: 0.073, P ≀ 0.0001; AR: 0.040, P ≀ 0.0035; and DRD2: 0.018, P ≀ 0.05. When evaluated in a multivariate regression analysis, they accounted collectively for 24% of the variance of breast carcinoma (P ≀ 0.0001). These genes accounted for 40% of the variance (P ≀ 0.00001) in a subset of age‐matched cases. Individual gene scores were added to form a breast carcinoma risk score (BCRS) that ranged from 0 to 17. When the BCRS was evaluated in a receiver operator characteristic plot, the area under the curve was 0.80 for the full set and 0.869 for the age‐matched set. The relative breast carcinoma risk for the different BCRS scores ranged from 0.10 to 11.9.

CONCLUSIONS

These results demonstrate a potentially powerful method of evaluating the additive effect of multiple breast carcinoma risk genes to form a potentially clinically useful assessment of women's risk for sporadic breast carcinoma. Cancer 2003;97:2160–70. Β© 2003 American Cancer Society.

DOI 10.1002/cncr.11340


πŸ“œ SIMILAR VOLUMES


C-myc oncogene expression: A marker for
✍ Dermot J. Hehir; Gerald McGreal; William O. Kirwan; William Kealy; Dr. Michael P πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 332 KB

In an attempt to identify patients at risk of breast cancer, 9E 10 c-myc monoclonal antibody was used to detect the oncogene products in 64 breast tissue biopsies. There were 44 specimens of benign breast disorders: 21 from patients who developed subsequent breast cancer, and 23 from patients who di

Gene therapy for carcinoma of the breast
✍ Stoff-Khalili, M A; Dall, P; Curiel, D T πŸ“‚ Article πŸ“… 2006 πŸ› Nature Publishing Group 🌐 English βš– 195 KB
Breast cancer risk associated with genot
✍ Ting-Chih Cheng; Shou-Tung Chen; Chiun-Sheng Huang; Yi-Ping Fu; Jyh-Cherng Yu; C πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 French βš– 138 KB πŸ‘ 1 views

## Abstract Estrogen has been suggested to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). To examine this hypothesis, we carried out a multigenic case‐control study of 469 incident breast cancer patients and 740 healthy controls to de